Statements about mechanism describe pathways reported in published animal and in vitro work. Human evidence varies. Growth hormone secretagogues occupy a strange position in the peptide landscape. They don't deliver exogenous hormone; instead, they coax the pituitary into releasing more of what it already makes. Hexarelin and CJC-1295 both trigger GH pulses, but their pharmacology diverges sharply. One acts fast and fades within hours. The other lingers for days, sustaining elevated IGF-1 without the sharp peaks. For track athletes chasing lean mass without the bloat or lipogenesis that often accompanies insulin-heavy protocols, the distinction matters. This comparison examines receptor affinity, pulse kinetics, documented body-composition shifts, and the practical trade-offs that separate a short-acting ghrelin mimetic from a long-acting GHRH analogue.
Receptor pathways and signalling duration
Hexarelin binds the ghrelin receptor (GHS-R1a) with high affinity, triggering a sharp GH pulse that peaks around 30 minutes post-injection and returns to baseline within two to three hours. Published research shows this pulse can elevate serum GH by something like 10- to 15-fold over baseline, though individual response varies with age and endogenous secretory capacity.
CJC-1295, particularly the DAC (drug-affinity complex) variant, binds GHRH receptors on somatotrophs and remains active for five to eight days. The extended half-life sustains a modest elevation in both GH and IGF-1, avoiding the pronounced peaks seen with shorter peptides. Studies in healthy adults report IGF-1 increases in the neighbourhood of 60 to 90 percent above baseline, held steady across multiple days.
Hexarelin also activates CD36 scavenger receptors in cardiac and skeletal muscle, a pathway unrelated to GH release. This secondary signalling may contribute to cardioprotective effects observed in animal models, but it complicates the interpretation of body-composition data because muscle glucose uptake can shift independently of systemic IGF-1.
Lean-mass accretion and nitrogen retention
The literature on hexarelin suggests that repeated dosing over four to six weeks produces modest increases in lean body mass, typically in the range of 1 to 2 kilograms when combined with resistance training. Nitrogen balance improves during the active dosing window, and some trials report a transient rise in basal metabolic rate.
CJC-1295 trials lasting 90 days have documented lean-mass gains closer to 2 to 3 kilograms, with a slower accretion curve but better retention after cessation. The sustained IGF-1 elevation appears to support protein synthesis without the rebound suppression that can follow pulsatile protocols.
Key differences in muscle-building kinetics include:
- Hexarelin delivers higher peak GH, which may enhance lipolysis acutely but does not guarantee superior nitrogen retention over weeks.
- CJC-1295 maintains elevated IGF-1 around the clock, supporting continuous anabolic signalling in muscle and connective tissue.
- Hexarelin's ghrelin-receptor activity stimulates appetite in many users, complicating calorie control during a lean-gain phase.
- CJC-1295 shows minimal appetite stimulation, making it easier to maintain a controlled surplus or even a slight deficit.
Neither peptide directly stimulates insulin secretion the way GHRP-6 does, so the risk of fat gain from hyperinsulinemia remains lower. Still, elevated GH can impair insulin sensitivity transiently, and individual response to carbohydrate timing becomes more important under either protocol.
Fat oxidation and substrate partitioning
Hexarelin's sharp GH pulses promote lipolysis during the two-hour window of peak hormone concentration. Published data indicate free-fatty-acid levels rise by something like 40 to 60 percent within 90 minutes of injection, then decline as GH clears. This pattern favours fat oxidation if training or fasted cardio coincides with the pulse, but offers little metabolic advantage outside that window.
CJC-1295 produces a flatter GH curve with sustained, moderate elevation. The result is a steady increase in 24-hour fat oxidation, measured by indirect calorimetry in controlled trials. Over weeks, this translates to a reduction in visceral adipose tissue by around 5 to 8 percent in subjects maintaining stable calorie intake.
Substrate partitioning under CJC-1295 appears to favour muscle over adipose during a caloric surplus, likely because continuous IGF-1 signalling keeps mTOR and Akt pathways primed in skeletal muscle. Hexarelin's pulsatile pattern does not sustain those pathways as consistently, so nutrient timing around the injection becomes more critical.
Neither peptide eliminates the need for a well-structured diet. GH secretagogues shift the margin, not the fundamentals. A 200-calorie daily surplus will still yield fat gain if protein intake sits below 1.6 grams per kilogram or if training volume is insufficient to drive hypertrophy.
Desensitisation, cortisol response, and cycle length
Hexarelin exhibits rapid desensitisation at the GHS-R1a receptor. Trials using daily dosing report a 30 to 50 percent reduction in GH response by week three, with near-complete attenuation by week six. Cycling protocols, two weeks on, one week off, partially restore sensitivity, but the rebound is incomplete.
CJC-1295 does not desensitise GHRH receptors to the same degree. Studies extending beyond 90 days show stable IGF-1 elevation with no significant decline in response magnitude. This makes it better suited to longer interventions, though the cost per milligram is higher and the logistics of refrigerated storage more demanding.
Cortisol co-secretion is a concern with any GH secretagogue. Hexarelin pulses can elevate cortisol by 20 to 40 percent during the same two-hour window as GH, potentially impairing recovery if injections are timed poorly. Evening doses, in particular, may disrupt sleep architecture despite the GH release.
CJC-1295 produces a smaller cortisol spike, distributed across the day rather than concentrated in a single pulse. The net catabolic load appears lower, though individual variation is wide. Athletes already managing high training stress should monitor subjective recovery markers, resting heart rate, grip strength, mood, when introducing either peptide.
Practical dosing, injection frequency, and stacking considerations
Hexarelin is typically dosed at 100 to 200 micrograms per injection, administered once or twice daily on an empty stomach. The short half-life means timing around training or sleep becomes part of the protocol design. Some users report better results with a pre-workout injection to capture the lipolytic window, while others prefer a bedtime dose to align with the natural nocturnal GH pulse.
CJC-1295 (with DAC) is dosed at 1 to 2 milligrams per week, often split into two injections to smooth the pharmacokinetic curve. The long half-life removes the need for daily pinning, which appeals to athletes who dislike frequent subcutaneous injections or who travel often.
Stacking either peptide with other compounds introduces additional variables:
- Combining hexarelin with a GHRH analogue (such as modified GRF 1-29) can amplify the GH pulse, but desensitisation accelerates and cortisol spikes become more pronounced.
- Adding IGF-1 LR3 to a CJC-1295 protocol risks over-suppressing endogenous GH production, because exogenous IGF-1 feeds back negatively on the pituitary.
- BPC-157 is sometimes run alongside either secretagogue to support tendon and ligament repair, though the mechanisms do not overlap and no synergy has been documented in controlled trials.
- Tesamorelin, a GHRH analogue approved for lipodystrophy, shares CJC-1295's receptor target but has a shorter half-life (around 30 minutes). It offers a middle ground between hexarelin's pulse and CJC-1295's plateau, though it is less widely available in research settings.
Injection-site rotation matters more with daily hexarelin dosing. Subcutaneous fibrosis can develop with repeated use of the same abdominal quadrant, reducing absorption consistency and creating palpable nodules that take weeks to resolve.
Which secretagogue fits a lean-gain phase?
Hexarelin suits short interventions where peak GH response and acute lipolysis are priorities. A four-week block timed around a competition taper or a photo shoot can deliver visible changes in muscle hardness and subcutaneous water, provided diet and training are dialled in. The appetite surge can be managed with high-satiety foods, lean protein, fibrous vegetables, and the desensitisation curve limits the temptation to extend the cycle beyond six weeks.
CJC-1295 fits longer phases where steady IGF-1 elevation supports continuous anabolic signalling without the logistical burden of daily injections. The slower accretion curve means results become apparent after week four or five, but retention after cessation is better. For athletes building into a season rather than peaking for a single event, the sustained approach often yields a better return on investment.
Neither peptide eliminates fat gain if calorie intake exceeds expenditure by a wide margin. GH secretagogues improve partitioning, they tilt the scales toward muscle and away from adipose, but they do not override thermodynamics. A 500-calorie surplus will still add fat, just less of it than the same surplus would produce without the peptide.
The choice also depends on tolerance for injection frequency and the ability to manage appetite. Hexarelin's ghrelin-receptor activity makes adherence harder for athletes who already struggle with hunger during a controlled surplus. CJC-1295's neutral effect on appetite simplifies meal planning and reduces the risk of unplanned binges that derail a lean-gain phase.
Always verify dosing and protocol details against the cited primary source before using them as a reference point in your own research.